Senolytic Therapeutics (STX) is a pharmaceutical company that develops a novel class of medicines by targeting damaged cells.

STX’s mission is to advance our portfolio of therapies to clinical trials and improve human condition.

We are challenged above all by the opportunity to improve the lives of patients and families affected by aging-associated diseases.

STX company is located in Boston (US) and Barcelona (Spain).